This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RSLS ReShape Lifesciences (RSLS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisEarningsHeadlinesInsider TradesShort InterestTrendsBuy This Stock About ReShape Lifesciences Stock (NASDAQ:RSLS) Get ReShape Lifesciences alerts:Sign Up Key Stats Today's Range$2.80▼$4.6550-Day Range$3.16▼$15.6852-Week Range$1.87▼$303.25Volume13.69 million shsAverage Volume3.32 million shsMarket Capitalization$8.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ReShape Lifesciences, headquartered in San Clemente, California, is a medical device company specializing in minimally invasive and non‐surgical therapies for obesity management and body contouring. The company’s core product portfolio includes endoscopic intragastric balloon systems that support physician‐led weight‐loss programs and non‐surgical cryolipolysis‐based devices for targeted adipose reduction without surgery. Under its ReShape Interventions division, the company markets a dual intragastric balloon system engineered to occupy gastric space, promote early satiety and aid comprehensive diet and lifestyle regimens. Through its OSPREY Medical division, ReShape provides non‐invasive body‐contouring platforms that harness controlled cooling and compression to reduce subcutaneous fat in outpatient aesthetic settings. Founded in 2010, ReShape Lifesciences has expanded beyond the United States to serve outpatient clinics and healthcare professionals in select European markets. The company partners with gastroenterologists, bariatric specialists and aesthetic practitioners to integrate its device technologies into multidisciplinary care pathways for patients seeking weight management and body‐shaping solutions. ReShape Lifesciences is guided by a leadership team with extensive expertise in medical device research, clinical development and regulatory compliance. The company continues to invest in product innovation and clinical studies aimed at enhancing the safety and efficacy of its minimally invasive and non‐invasive therapies in the growing obesity and aesthetic care markets.AI Generated. May Contain Errors. Read More Receive RSLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReShape Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RSLS Stock News HeadlinesReshape Lifesciences Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comReShape Lifesciences Inc trading halted, news pendingAugust 15, 2025 | msn.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.September 19 at 2:00 AM | Investors Alley (Ad)Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND TomorrowAugust 14, 2025 | finance.yahoo.com3 Penny Stocks to Watch Now, 8/14/25August 14, 2025 | msn.comVyome Therapeutics Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HINDAugust 14, 2025 | finanznachrichten.deVyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HINDAugust 13, 2025 | finance.yahoo.comReShape Lifesciences Stock Rocketed 37% Today – Here’s WhyAugust 13, 2025 | msn.comSee More Headlines RSLS Stock Analysis - Frequently Asked Questions How were ReShape Lifesciences' earnings last quarter? ReShape Lifesciences Inc. (NASDAQ:RSLS) posted its quarterly earnings results on Thursday, August, 14th. The medical device company reported ($9.00) EPS for the quarter. The medical device company earned $1.24 million during the quarter. ReShape Lifesciences had a negative net margin of 69.71% and a negative trailing twelve-month return on equity of 547.65%. When did ReShape Lifesciences' stock split? ReShape Lifesciences shares reverse split on Monday, August 18th 2025.The 1-4 reverse split was announced on Wednesday, August 13th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of ReShape Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that ReShape Lifesciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Digital Turbine (APPS), Nano Dimension (NNDM), CrowdStrike (CRWD) and Company Calendar Last Earnings8/14/2025Today9/19/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:RSLS CIK1371217 Webwww.reshapelifesciences.com Phone(949) 429-6680FaxN/AEmployees50Year Founded2002Profitability EPS (Trailing Twelve Months)($108.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.13 million Net Margins-69.71% Pretax Margin-47.82% Return on Equity-547.65% Return on Assets-79.89% Debt Debt-to-Equity RatioN/A Current Ratio1.53 Quick Ratio0.91 Sales & Book Value Annual Sales$8.01 million Price / Sales1.06 Cash FlowN/A Price / Cash FlowN/A Book Value($8.66) per share Price / Book-0.36Miscellaneous Outstanding Shares2,690,000Free Float2,386,000Market Cap$8.49 million OptionableNot Optionable Beta1.16 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:RSLS) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReShape Lifesciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ReShape Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RSLS Stock Alerts